Columbia Sportswear Company (COLM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of ten directors, including Timothy P. Boyle, Kevin Mansell, and others, is up for vote at the annual meeting.
Ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2026 is proposed.
Advisory, non-binding vote on executive compensation is included.
Approval of the Amended and Restated 2020 Stock Incentive Plan is on the agenda.
Shareholder proposal regarding proxy access is presented, with the board recommending a vote against it.
Board of directors and corporate governance
Ten nominees are listed for election to the board, reflecting a mix of current and potentially new directors.
Audit committee and external auditor matters
Proposal to ratify Deloitte & Touche LLP as the independent auditor for the 2026 fiscal year.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Columbia Sportswear Company
- 2026 annual meeting covers director elections, pay, stock plan, and proxy access, with Board opposition to proxy access.COLM
Proxy filing24 Apr 2026 - Q4 sales fell 2% but margin rose; 2026 outlook sees 1–3% growth and tariff pressure.COLM
Q4 20254 Feb 2026 - Q2 sales fell 8% with a net loss, but strong cash and inventory cuts support a steady outlook.COLM
Q2 20242 Feb 2026 - Q3 sales fell 5% as North America lagged, but gross margin rose and EPS guidance increased.COLM
Q3 202417 Jan 2026 - 2025 outlook targets modest growth, margin gains, and brand investment, led by EMEA and LAAP.COLM
Q4 20248 Jan 2026 - Q1 sales up 1%, margin gains, but outlook withdrawn amid tariff and macro uncertainty.COLM
Q1 20256 Jan 2026 - Board recommends all director nominees, auditor ratification, and opposes new GHG targets.COLM
Proxy Filing1 Dec 2025 - Annual meeting to address director elections, auditor, pay, and GHG targets proposal.COLM
Proxy Filing1 Dec 2025 - Q3 2025 sales up 1% on global strength, but profit fell on impairments and higher costs.COLM
Q3 20256 Nov 2025